Minireview: The glucagon-like peptides

Endocrinology

Volumn 142, Issue 2, 2001, Pages 521-527

  Drucker, D J ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; GLUCOSE;

ABSORPTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CRYPT CELL; DIABETES MELLITUS; ENERGY ABSORPTION; ENTEROPATHY; ENZYME ACTIVITY; FOOD INTAKE; GLUCAGON RELEASE; GLUCOSE HOMEOSTASIS; HYPOTHALAMUS HYPOPHYSIS SYSTEM; INSULIN RELEASE; INSULIN SYNTHESIS; INTESTINE ABSORPTION; INTESTINE MUCOSA; INTESTINE MUCOSA PERMEABILITY; INTESTINE SECRETION; LARGE INTESTINE; NEUROSECRETORY CELL; NONHUMAN; NUTRIENT; PANCREAS ISLET CELL; PRIORITY JOURNAL; SHORT SURVEY; SMALL INTESTINE; STOMACH EMPTYING;

EID: 0035106978     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.142.2.7983     Document Type: Short Survey

References (100)

1. The glucagon-like peptides
2. Glucagon-like peptide 2
3. The glucagon-like peptides
4. Role of prohormone convertases in the tissue-specific processing of proglucagon
5. Effects of fasting, refeeding and intraluminal triglyceride on proglucagon expression in jejunum and ileum
6. Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop
7. Gastrin-releasing peptide is a novel mediator of proximal nutrient-induced proglucagon-derived peptide secretion from the distal gut
8. Role of the vagus nerve in mediating proximal nutrient-induced glucagon- like peptide-1 secretion
9. Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum
10. Intestinal growth is associated with elevated levels of glucagon-like peptide-2 in diabetic rats
11. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV
12. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo
13. Enzymatic and renal-dependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in the rat
14. Circulating and tissue forms of the intestinal growth factor, glucagon-like peptide 2
15. Regulation of the biological activity of glucagon-like peptide 2 by dipeptidyl peptidase IV
16. Secretion of the intestinotropic hormone glucagon-like peptide 2 is differentially regulated by nutrients in humans
17. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine
18. In vivo and in vitro degradation of glucagon-like peptide-2 in humans
19. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats
20. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26
21. Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides
22. Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon
23. The influence of the colon on postprandial glucagon-like peptide 1 (7-36) amide concentration in man
24. Circulating levels of glucagon-like peptide-2 in human subjects with inflammatory bowel disease
25. Impaired meal-stimulated glucagon-like peptide-2 response in ileal resected short bowel patients with intestinal failure
26. Effects of subcutaneous glucagon-like peptide 1 (GLP-1[amide]) in patients with NIDDM
27. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans
28. A role for glucagon-like peptide-1 in the central regulation of feeding
29. Intraventricular GLP-1 reduces short- but not long-term food intake or body weight in lean and obese rats
30. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide receptor gene
31. Effects of aging and a high fat diet on body weight and glucose control in GLP-1R-/- mice
32. Elimination of GLP-1R signaling does not modify weight gain and islet adaptation in mice with combined disruption of leptin and GLP-1 action
33. Sustained expression of exendin-4 does not perturb glucose homeostasis, β cell mass or food intake in metallothionein-preproexendin transgenic mice
34. Central infusion of GLP-1, but not leptin, produces conditioned taste aversion in rats
35. Central infusion of glucagon-like peptide-1-(7-36) amide (GLP-1) receptor antagonist attenuates lithium chloride-induced c-Fos induction in rat brainstem
36. Interoceptive stress activates glucagon-like peptide-1 neurons that project to the hypothalamus
37. Glucagon-like peptide (GLP-1) is involved in the central modulation of fecal output in rats
38. A functional role for central glucagon-like peptide-1 receptors in lithium chloride-induced anorexia
39. The role of CNS glucagon-like peptide-1 (7-36) amide receptors in mediating the visceral illness effects of lithium chloride
40. Neuroendocrine function in mice with complete disruption of GLP-1 receptor signaling
41. Central infusions of leptin and GLP-1-(7-36) amide differentially stimulate c-FLI in the rat brain
42. Glucagon-like peptide-1 (GLP-1) releases thyrotropin (TSH): Characterization of binding sites for GLP-1 on alpha-TSH cells
43. Glucagon-like peptide-1 stimulates luteinizing hormone releasing hormone secretion in a rodent hypothalamic neuronal cell line (GT1-7)
44. Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat
45. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line
46. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37)
47. Glucagon-like peptide 1 elevates cytosolic calcium in pancreatic β-cells independently of protein kinase A
48. Glucagon-like peptide 1 stimulates insulin gene promoter activity by protein kinase A-independent activation of the rat insulin 1 gene cAMP response element
49. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells
50. 2+ signaling in mouse pancreatic islets with GLP-1 receptor null phenotype
51. Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons
52. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: Studies with the antagonist exendin
53. Glucagon-like peptide 1 is a physiological incretin in rat
54. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans
55. GLP-1 but not GIP regulates fasting and non-enteral glucose clearance in mice
56. Initiation of increased pancreatic islet growth in young normoglycemic mice (Umea +/?)
57. Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells
58. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats
59. Insulinotropic glucagon-like peptide-1 agonists stimulate expression of homeodomain protein IDX-1 and increase β-cell mass in mouse pancreas
60. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide 1 receptor
61. Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse
62. Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs
63. Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes
64. Interactions of exendin-(9-39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats
65. Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats
66. Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations
67. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats
68. Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats
69. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2
70. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients
71. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas
72. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure
73. Glucagon-like peptide-1 (GLP-1): A trial of treatment in non-insulin-dependent diabetes mellitus
74. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes
75. CD26, let it cut or cut it down
76. Oral delivery of glucagon-like peptide-1 in a modified polymer preparation normalizes basal glycemia in diabetic db/db mice
77. GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions
78. Trout and chicken proglucagon: Alternative splicing generates mRNA transcripts encoding glucagon-like peptide 2
79. Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard
80. Induction of intestinal epithelial proliferation by glucagon-like peptide 2
81. Endocrine tumour in kidney affecting small bowel structure, motility, and absorptive function
82. Glucagonoma syndrome demonstrating giant duodenal villi
83. Intestinal growth-promoting properties of glucagon-like peptide 2 in mice
84. The effect of gastric inhibitory polypeptide and glucagon like peptides on intestinal hexose transport
85. Glucagon-like peptide-2 inhibits centrally reduced antral motility in pigs
86. Inhibition of sham feeding-stimulated human gastric acid secretion by glucagon-like peptide-2
87. Glucagon-like peptide-2 enhances epithelial barrier function of both transcellular and paracellular pathways in the mouse
88. Prevention of parenteral nutrition-induced gut hypoplasia by coinfusion of glucagon-like peptide-2
89. Intestinal response to growth factors administered alone or in combination with h[Gly2]-glucagon-like peptide 2
90. Glucagon-like peptide 2 is a potent growth factor for small intestine and colon
91. GLP-2 augments the adaptive response to massive intestinal resection in rat
92. Treatment of short bowel patients with glucagon-like peptide-2 (GLP-2), a newly discovered intestinotrophic, anti-secretory, and transit-modulating peptide
93. Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis
94. Human [Gly2]-GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis
95. Glucagon-like peptide-2 analogue enhances intestinal mucosal mass after ischemia and reperfusion
96. Ontogeny of the glucagon-like peptide-2 receptor axis in the developing rat intestine
97. Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2
98. Enteroendocrine localization of GLP-2 receptor expression
99. Identification of glucagon-like peptide-2 (GLP-2)-activated signaling pathways in baby hamster kidney fibroblasts expressing the rat GLP-2 receptor
100. The glucagon-like peptide-2 receptor mediates direct inhibition of cellular apoptosis via a cAMP-dependent protein kirtase pathway